Psychiatry and Neurology, Neurology · Baton Rouge, LA
NPI
1902873516
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
10101 Park Rowe Ave, Suite 200
Baton Rouge, LA, 70810
Phone (225) 769-2200
Groups this clinician bills Medicare through
Medicare paid, 2024
$280K
37,954 services
Medicare patients, 2024
560
Average age 74
Drug cost, 2024
$4.9M
6,146 prescriptions
Company payments, 2025
$59K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gerald J Calegan II was code J0588 (injection, incobotulinumtoxin a, 1 unit), 28,050 times for 52 patients. In total Gerald J Calegan II billed 37,954 services in 37 codes, and Medicare paid $280K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-05-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0588 Injection, incobotulinumtoxin a, 1 unit | Office | 28,050 | 52 | $4.03 | $113K |
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 5,800 | 16 | $4.81 | $28K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 423 | 319 | $11.60 | $4,908 |
| 99213 Office E&M - Established | Office | 359 | 266 | $56.42 | $20K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 282 | 139 | $46.69 | $13K |
| 99214 Office E&M - Established | Office | 190 | 158 | $85.06 | $16K |
| 99205 Office E&M - New | Office | 119 | 119 | $147.84 | $18K |
| 64616 Musculoskeletal | Office | 103 | 36 | $133.79 | $14K |
| 95886 Electrical Nerve Conductivity | Office | 60 | 36 | $66.84 | $4,011 |
| 64612 Musculoskeletal | Office | 58 | 21 | $123.78 | $7,179 |
| 95970 Electrical Nerve Conductivity | Office | 53 | 34 | $11.70 | $620 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 41 | 29 | $35.59 | $1,459 |
| 95983 Electrical Nerve Conductivity | Office | 33 | 27 | $29.72 | $981 |
| 64642 Musculoskeletal | Office | 31 | 14 | $75.69 | $2,347 |
| 95913 Electrical Nerve Conductivity | Office | 26 | 26 | $198.08 | $5,150 |
By year: 2022 $230K for 28,972 services; 2023 $239K for 30,142 services; 2024 $280K for 37,954 services.
Medicare prescription drug claims, 2024
In 2024, the drug Gerald J Calegan II prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 1,088 prescriptions and refills. In total Gerald J Calegan II wrote 6,146 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 1,088 | 2,297 | 278 | $43K |
| Nuplazid Pimavanserin Tartrate | 459 | 465 | 54 | $2.2M |
| Rytary Carbidopa/Levodopa | 410 | 604 | 63 | $450K |
| Clonazepam Generic | 375 | 375 | 59 | $2,026 |
| Rasagiline Mesylate Generic | 291 | 631 | 71 | $47K |
| Memantine Hcl Generic | 251 | 538 | 69 | $6,173 |
| Propranolol Hcl Generic | 240 | 457 | 61 | $4,869 |
| Gabapentin Generic | 213 | 354 | 63 | $3,587 |
| Levetiracetam Generic | 185 | 379 | 43 | $5,676 |
| Primidone Generic | 172 | 353 | 47 | $4,913 |
| Donepezil Hcl Generic | 156 | 318 | 51 | $1,500 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 136 | 306 | 40 | $3,715 |
| Quetiapine Fumarate Generic | 135 | 201 | 35 | $1,968 |
| Entacapone Generic | 134 | 227 | 32 | $16K |
| Propranolol Hcl Er Propranolol Hcl | 128 | 294 | 38 | $6,058 |
Brand drugs: 1,425 claims; generic drugs: 4,705 claims; opioid claims: 21.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gerald J Calegan II $59K ($59K in general payments such as food, travel and fees) from 33 companies. The largest payer was ACADIA Pharmaceuticals Inc with $31K.
| Company | Payments | Amount |
|---|---|---|
| ACADIA Pharmaceuticals Inc ACAD | 52 | $31K |
| Teva Pharmaceuticals USA, Inc. TEVA | 12 | $12K |
| Neurocrine BioSciences, Inc. NBIX | 65 | $6,217 |
| Abbott Laboratories ABT | 34 | $4,945 |
| Abbvie Inc. ABBV | 65 | $850 |
| Biogen, Inc. BIIB | 20 | $424 |
| Pfizer Inc. PFE | 38 | $391 |
| Amneal Pharmaceuticals LLC AMRX | 16 | $286 |
| Eisai Inc. 4523.T | 6 | $223 |
| Lundbeck LLC | 10 | $201 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.